16 completed, 8 not yet recruiting, 5 recruiting, 4 terminated. 11 Phase 3, 5 Phase 2, 5 Phase 4, 3 Phase 1, 1 Not applicable.
Follow avibactam, ceftazidime drug combination: new trials by email Literature Review of avibactam, ceftazidime drug combination trials Research Report on avibactam, ceftazidime drug combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Cefepime-Zidebactam, Ceftazidime-avibactam with or without Colistin - Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP) | Phase 3 | Not yet recruiting | Wockhardt | 324 | 2026-10-28 | 2026-10-21 |
| Aztreonam-Avibactam in Immunocompromised Hosts Aztreonam-Avibactam, Ceftazidime-Avibactam Plus Aztreonam - Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection | Recruiting | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | 814 | 2026-10-14 | 2026-10-22 | |
| Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation Ceftazidime - Avibactam ( CAZ-AVI), Meropenem-Vaborbactam, Imipenem+Relebactam - Liver Transplant, Carbapenem-resistant Enterobacterales | Phase 3 | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 168 | 2026-10-01 | 2026-08-12 |
| This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis Ertapenem-zidebactam, Ceftazidime-Avibactam, Ertapenam-Zidebactam - Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis | Phase 2 | Not yet recruiting | Wockhardt | 279 | 2026-09-30 | 2026-09-24 |
| Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients Ceftazidime-avibactam, Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance - Hematologic Neoplasms, Gram-Negative Bacterial Infections | Not yet recruiting | Sizhou Feng | 60 | 2026-07-09 | 2026-07-14 | |
| A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia YK-1169, Ceftazidime-avibactam Injection - Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) | Phase 3 | Not yet recruiting | Nanjing Yoko Biomedical Co., Ltd. | 590 | 2026-06-04 | 2026-06-08 |
| A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP Meropenem and Pralurbactam, Ceftazidime-avibactam - Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 420 | 2026-01-22 | 2026-02-17 |
| Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients. Carbapenems, Anti-Gram-positive agent, Antifungal agent - Febrile Neutropenia | Recruiting | Shanxi Bethune Hospital | 20 | 2025-09-22 | 2025-10-02 | |
| A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections Ceftazidime± avibactam with fosfomycin, Ceftazidime± avibactam with placebo - Gram Negative Infections, Sepsis and Septic Shock | Phase 3 | Recruiting | Angela HUTTNER | 100 | 2025-08-25 | 2025-09-26 |
| Optimising TREATment for Severe Gram-Negative Bacterial Infections Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem - Bloodstream Infection, Ventilator Associated Bacterial Pneumonia | Phase 4 | Recruiting | National University of Singapore | 600 | 2025-04-21 | 2025-06-04 |
| Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections. Meropenem Injection, Ceftazidime-avibactam, Teicoplanin - Acute-On-Chronic Liver Failure | Not applicable | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 150 | 2025-02-10 | 2025-02-10 |
| Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI Meropenem and Pralurbactam, Saline, Ceftazidime-avibactam - Intra-abdominal Infections | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 786 | 2024-10-31 | 2024-10-09 |
| Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model ceftazidime avibactam - ECMO, Carbapenem-Resistant Enterobacteriaceae Infection | Not yet recruiting | Sichuan Provincial People's Hospital | 50 | 2024-01-01 | 2024-01-18 | |
| Comparing Oral Versus Parenteral Antimicrobial Therapy Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem - Endovascular Infection, Bone and Joint Infection | Phase 4 | Terminated | West Virginia University | 94 | 2023-08-04 | 2025-08-26 |
| Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections Ceftazidime-avibactam, Colistin - Carbapenem-Resistant Enterobacteriaceae Infection | Phase 3 | Terminated | King Faisal Specialist Hospital & Research Center | 29 | 2022-06-01 | 2024-06-14 |
| Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults Zavicefta, Ceftazidime-Avibactam, Best Available Treatment - Urinary Tract Infection, Acute Pyelonephritis | Phase 4 | Completed | Pfizer | 60 | 2021-08-26 | 2024-10-21 |
| Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients Ceftazidime-avibactam - Severe Sepsis, Carbapenem Resistant Bacterial Infection | Completed | First Affiliated Hospital of Zhejiang University | 33 | 2021-06-01 | 2026-09-10 | |
| Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP) Zavicefta, Ceftazidime-Avibactam - Hospital-Acquired Pneumonia | Phase 4 | Completed | Pfizer | 235 | 2021-05-21 | 2024-09-19 |
| Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections Ceftazidime-avibactam - Gram Negative Infections | Completed | Pfizer | 189 | 2021-01-29 | 2024-08-14 | |
| Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia Ceftazidime-avibactam - Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia | Phase 1 | Terminated | Pfizer | 4 | 2020-06-15 | 2022-09-09 |
Showing 20 of 34. Sign in to see all of them.
Bacterial Infections (3) · Healthcare-Associated Pneumonia (3) · Sepsis (3) · Critical Illness (2) · Gram-Negative Bacterial Infections (2) · Intraabdominal Infections (2) · Pneumonia, Ventilator-Associated (2) · Acute-On-Chronic Liver Failure (1) · Bacteremia (1) · Cystic Fibrosis (1) · Enterobacteriaceae Infections (1) · Febrile Neutropenia (1) · Hematologic Neoplasms (1) · Pseudomonas Infections (1) · Renal Insufficiency (1)
Pfizer (11) · Qilu Pharmaceutical Co., Ltd. (2) · Wockhardt (2) · Angela HUTTNER (1) · Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno (1) · First Affiliated Hospital of Zhejiang University (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Institute of Liver and Biliary Sciences, India (1) · King Abdul Aziz Specialist Hospital (1) · King Faisal Specialist Hospital & Research Center (1) · Maimónides Biomedical Research Institute of Córdoba (1) · Michigan State University (1) · Nanjing Yoko Biomedical Co., Ltd. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National University of Singapore (1)
United States (11) · China (10) · Poland (6) · Romania (6) · Taiwan (6) · Czechia (5) · Greece (5) · India (5) · Russia (5) · Spain (5) · Turkey (Türkiye) (5) · Argentina (4) · Bulgaria (4) · Croatia (4) · Hungary (4)
Paul Newell, MBBS, MRCP (3) · Arif R. Sarwari, MD, MSc, MBA (1) · Christina Rose, Pharm.D. (1) · Diego Torres, MD (1) · Gary E Stein, PharmD (1) · Hakeam Hakeam (1) · Joy J. Juskowich, MD (1) · Maddalena Giannella, MD, PhD (1) · Maximiliano Gabriel Castro, MD (1) · Paul A Newell, MBBS, MRCP (1) · Paul Beringer, PharmD (1) · Ryan Shields, Pharm D (1)
PMID 29912399, PMID 30061279, PMID 30221827, PMID 32602065, PMID 37700689, PMID 27313268, PMID 34687548, PMID 27872067, PMID 28363526, PMID 28784670, PMID 30910899, PMID 31306396, PMID 31335570, PMID 40251980, PMID 41419216, PMID 42829121
2014 (2), 2018 (2), 2025 (1), 5UM1AI104681-09 (1)